Table 22.
Cost-effectiveness (Euro per QALY gained) for the treatment of osteoporosis, hypertension and hyperlipidaemia for women in different risk groups based on a societal perspective. (Adapted from [166])
| Age (years) | Risk category | |||
|---|---|---|---|---|
| I | II | III | IV | |
| Osteoporosis | ||||
| 50 | 80,000 | 53,000 | 29,000 | 21,000 |
| 60 | 50,000 | 34,000 | 22,000 | 16,000 |
| 70 | 36,000 | 22,000 | 14,000 | 7,600 |
| 80 | 21,000 | 9,300 | 5,500 | c.s. |
| Hypertension | ||||
| 50 | 64,000 | 61,000 | 44,000 | 23,000 |
| 60 | 46,000 | 37,000 | 33,000 | 21,000 |
| 70 | 33,000 | 32,000 | 29,000 | 24,000 |
| 80 | 37,000 | 35,000 | 34,000 | 31,000 |
| Hyperlipidaemia | ||||
| 50 | 41,000 | 27,000 | 13,000 | 5,500 |
| 60 | 40,000 | 27,000 | 19,000 | 16,000 |
| 70 | 36,000 | 32,000 | 26,000 | 26,000 |
| 80 | 43,000 | 38,000 | 36,000 | 36,000 |